Rigel Pharmaceuticals, Incorporated

Terran Biosciences, Inc.

Evotec Ag

Renovis, Inc.

Other

Deciduous Therapeutics, Inc.

Rigl Pharmaceutical, Inc.

Matthew Duncton

Rajinder Paul Singh

Rao Kolluri

Salvador Alvarez

Sacha Holland

Kin Tso

Jing Zhang

Esteban Masuda

Thilo J Heckrodt

Hui Li

Donald G Payan

Yan Chen

Rose Yen

Ryan Kelley

Somasekhar Bhamidipati

Jiaxin Yu

Ihab S Darwish

Samuel Clark

Michael G Kelly

John Kincaid

John Yudhistir Ramphal

Darren J McMurtrie

Carlos A Valdez

Donogh John Roger O'Mahony

Haoran Zhao

Zhi-Liang Wei

Satyanarayana Janagani

Shihai Gu

Emily Stauffer

Guoxian Wu

Simon Shaw

Xiang Xu

Zhan Wang

Yasumichi Hitoshi

Sarkiz D Issakani

Carl J Kaub

Matthew Cox

Ravindra B Upasani

Maria De Los Angeles Estiarte-Martinez

Nan Lin

Jianhua He, Legal Representative

Martin D Burke

Huí Li

Kiran Sahasrabudhe

Robin Mansukhani

Thomas Bobinski

Sarkiz Issakani

John Ramphal

Darren Mcmurtrie

Mathew Cox

The present disclosure is directed to salt and solid forms of (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE and methods of treating neurological disorder and/or a psychiatric disorder in a subject in need thereof.

Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine

Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine

Disclosed herein are xanomeline analogs, as well as methods for making and using the analogs to, for example, treat neuropsychiatric disorders.

Analogs of xanomeline

Described herein are isotopically enriched analogs of methylone (e.g., deuterated analogs of methylone (e.g., (S)-methylone and (R)-methylone) with improved characteristics. Also described herein are salts (such as hydrochloride salt) and solid forms (e.g., crystalline forms) of methylone. Also described herein are stereoisomers (e.g., enantiomers) of methylone. The present disclosure also provides methods of making and methods of use of the methylone or methylone analogs and solid forms of 3,4-methylenedioxy-N-ethylcathinone hydrochloride described herein to treat brain and neurological disorders such as depression.

Isotopologues salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof

Compounds as depicted below and structural analogues thereof for activating invariant natural killer T cells (iNKT) cells are provided. Such compounds may be used to activate iNKT cells and induce an increase in the production of one or more cytokines, such as IFNγ, IL-2, IL-4, IL-6 and TNFα. Activated iNKT cells may be used to selectively reduce the presence of or eliminate inflammatory senescent cells, such as senescent cells having an inflammatory secretome (SASP). Also provided are pharmaceutical compositions comprising such compounds.

Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Nrf2 activating compounds and uses thereof

Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R, R, R, R, Y and X are as described herein. In certain embodiments, a compound disclosed herein activates AMPK, and can be used to treat disease by activating the AMPK pathway.

Direct AMPK activators

Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Fumarate analogs and uses thereof

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Protein kinase C inhibitors and uses thereof

The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Tetrazolones as a carboxylic acid bioisosteres

Growing community of inventors

San Bruno, CA, United States of America

Matthew Duncton